Because endocytic transport is among the earliest to display neuropathological abnormalities during early-stage AD and is believed to precede Aβ deposition35,36, a new AD therapeutic strategy towards control of APP processing via action of SNX family proteins could be promising. This evidence concerns the gene ANXA7 and Alzheimer disease.